Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double‐blind placebo‐controlled trial-Reference-Cited by-同舟云学术

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double‐blind placebo‐controlled trial

Published:1998-05 Issue:2 Volume:101 Page:280-286
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:British Journal of Haematology

Author:

Brincker Hans¹,Westin Jan²,Abildgaard Niels³,Gimsing Peter⁴,Turesson Ingemar⁵,Hedenus Michael⁶,Ford John⁷,Kandra Albert⁷

Affiliation:

1. Department of Haematology, Odense University Hospital, Odense, Denmark,

2. Department of Haematology, Lund University Hospital, Lund, Sweden,

3. Department of Haematology, Aarhus University Hospital, Århus, Denmark,

4. Department of Haematology, Rigshospitalet, Copenhagen, Denmark,

5. Department of Haematology, University Hospital MAS, Malmö, Sweden,

6. Department of Medicine, Sundsvall Hospital, Sundsvall, Sweden,

7. Ciba‐Geigy Ltd, Clinical Research, Basle, Switzerland

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2141.1998.00695.x

Reference25 articles.

1. Effect of daily etidronate on the osteolysis of multiple myeloma;Belch A.R.;Journal of Clinical Oncology,1991

2. Berenson J.R.(1997)Bisphosphonates in multiple myeloma.Cancer Suppl. 80 16611667.

3. Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

4. Treatment of malignancy‐associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate;Body J.J.;Journal of Clinical Oncology,1986

5. 1993) CGP 23339 A. Urinary excretion of pamidronate disodium in patients after a single peroral dose of 300 mg pamidronate disodium (enteric‐coated pellet capsules) taken either fasting before or during breakfast. Ciba‐Geigy Ltd Basle Switzerland July 1993.

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone Metabolism in Cancer;Central Nervous System Metastases;2020

Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma

;OncoTargets and Therapy;2019-10

3. Bone Disease;Hematologic Malignancies;2018

4. Bisphosphonates in multiple myeloma: an updated network meta-analysis;Cochrane Database of Systematic Reviews;2017-12-18

5. Practical Considerations for Bone Health in Multiple Myeloma;Personalized Therapy for Multiple Myeloma;2017-11-01